علاج سرطان الغدد الليمفاوية الأولي للجهاز العصبي المركزي المنتكس أو المقاوم للعلاج

References

DOI: 10.1093/neuonc/noac196

• MTX re-challenge should be considered in recurrent PCNSL patients who previously responded to HD MTX (Level C).
• HDC/ASCT is a valid therapeutic option in patients aged <70 years with chemosensitive relapsing PCNSL especially in patients without prior ASCT (Level B).
• Salvage WBRT may be proposed in radiotherapy-naïve patients; it may be preceded by induction chemotherapy (Good Practice Point).
• Bruton Tyrosine kinase inhibitors, imids, immune checkpoint inhibitors and CART have shown clinical activity as single agents in relapsing PCNSL and may be considered in salvage treatments.